Document is current
Any future updates will be listed below
-
Authors
Dear, Richard https://orcid.org/0000-0002-1670-6767
Wagstyl, Konrad
Seidlitz, Jakob https://orcid.org/0000-0002-8164-7476
Markello, Ross D. https://orcid.org/0000-0003-1057-1336
Arnatkevičiūtė, Aurina https://orcid.org/0000-0003-4098-7084
Anderson, Kevin M.
Bethlehem, Richard A. I. https://orcid.org/0000-0002-0714-0685
,
Raznahan, Armin https://orcid.org/0000-0002-5622-1190
Bullmore, Edward T.
Vértes, Petra E. https://orcid.org/0000-0002-0992-3210
- License Information
-
More Information
Article History
Received: 1 October 2022
Accepted: 18 March 2024
First Online: 22 April 2024
Competing interests
: K.M.A. is an employee of Neumora Therapeutics. R.D.M. is an employee of Octave Biosciences. E.T.B. has consulted for Boehringer Ingelheim, SR One, GlaxoSmithKline, Sosei Heptares and Monument Therapeutics. All other authors have no disclosures to make.
